Bone Marrow Transplantation News

Blinatumomab appeared as safe and effective in older patients as it did in younger patients with relapsed and refractory B-precursor acute lymphoblastic leukemia, according to the results of two phase 2 studies.

A prolonged course of lenalidomide maintenance following autologous hematopoietic stem cell transplantation improved survival outcomes without increasing the incidence of second primary malignancies in patients with multiple myeloma, according to retrospective study results.

A pivotal phase 3 study designed to evaluate letermovir for the prevention of clinically significant cytomegalovirus infection in high-risk patients who underwent bone marrow transplant met its primary endpoint, according to the agent’s manufacturer.

The University of Michigan Comprehensive Cancer Center appointed four people to leadership positions to help oversee its research operations.

Bone marrow transplantation using unrelated donor marrow conferred promising rates of 1-year EFS for children with severe sickle cell disease, according to phase 2 study results published in Blood.

The FDA granted breakthrough therapy designation to the novel graft modality NiCord for bone marrow transplantation in patients with hematological malignancies, according to the modality’s manufacturer.

The American Society for Clinical Pathology has added five recommendations for laboratory treatments and tests that physicians and patients should question, according to a press release from the organization.

Somatic mutations in ASXL1, RUNX1 and TP53 appeared independently associated with poor outcomes and shorter OS in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia, according to study results published in Journal of Clinical Oncology.

Extraordinary therapeutic advances, a renewed bipartisan commitment to medical research and the launch of the national cancer moonshot initiative have reinforced the importance of scientific investigation in the fight against cancer.

Vice President Joe Biden outlined a plan to improve the efficiency and transparency of the U.S. clinical research system as part of the national cancer moonshot initiative.